國立虎尾科技大學 |

TRAIL, Fas Ligand, TNF and TLR3 in cancer

Record Type:	Language materials, printed : Monograph/item
Title/Author:	TRAIL, Fas Ligand, TNF and TLR3 in cancer/ edited by Olivier Micheau.
other author:	Micheau, Olivier.
Published:	Cham :Springer International Publishing : : 2017.,
Description:	xiii, 317 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
Subject:	Cancer - Treatment. -
Online resource:	http://dx.doi.org/10.1007/978-3-319-56805-8
ISBN:	9783319568058

TRAIL, Fas Ligand, TNF and TLR3 in cancer
TRAIL, Fas Ligand, TNF and TLR3 in cancer[electronic resource] /edited by Olivier Micheau. - Cham :Springer International Publishing :2017. - xiii, 317 p. :ill., digital ;24 cm. - Resistance to targeted anti-cancer therapeutics,v.122196-5501 ;. - Resistance to targeted anti-cancer therapeutics ;v.4..

Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer -- TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer -- IAPs and Resistance to Death Receptors in Cancer -- Bcl-2 Proteins and TRAIL Resistance in Melanoma -- Regulation of Caspase-Mediated Apoptosis by the Tumor Suppressor Par-4 -- Stem Cell Regulation by Death Ligands and Their Use in Cell Therapy -- Atypical Immune Functions of CD95/CD95L -- TLR3 is a Death Receptor Target in Cancer Therapy -- Fas/CD95, Lipid Rafts and Cancer -- Role of Sphingolipids in Death Receptor Signalling -- Post-Translational Modifications and Death Receptor Signalling -- System Modeling of Receptor-Induced Apoptosis.

This volume provides the current understanding of death receptor's/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy. But an increasing body of evidence suggests that some of these receptors may also contribute to tumorigenesis, or that new players such as TLR3 may be targeted for cancer therapy due to their ability to behave like death receptors.

ISBN: 9783319568058

Standard No.: 10.1007/978-3-319-56805-8doiSubjects--Topical Terms:

661325
Cancer
--Treatment.

LC Class. No.: RC270.8

Dewey Class. No.: 616.99406

TRAIL, Fas Ligand, TNF and TLR3 in cancer
LDR:02301nam a2200325 a 4500 001 922766
003 DE-He213
005 20170703154220.0
006 m d
007 cr nn 008maaau
008 190625s2017 gw s 0 eng d
020 $a 9783319568058 $q (electronic bk.)
020 $a 9783319568041 $q (paper)
024 7 $a 10.1007/978-3-319-56805-8 $2 doi
035 $a 978-3-319-56805-8
040 $a GP $c GP
041 0 $a eng
050 4 $a RC270.8
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99406 $2 23
090 $a RC270.8 $b .T766 2017
245 0 0 $a TRAIL, Fas Ligand, TNF and TLR3 in cancer $h [electronic resource] / $c edited by Olivier Micheau.
260 $a Cham : $c 2017. $b Springer International Publishing : $b Imprint: Springer,
300 $a xiii, 317 p. : $b ill., digital ; $c 24 cm.
490 1 $a Resistance to targeted anti-cancer therapeutics, $x 2196-5501 ; $v v.12
505 0 $a Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer -- TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer -- IAPs and Resistance to Death Receptors in Cancer -- Bcl-2 Proteins and TRAIL Resistance in Melanoma -- Regulation of Caspase-Mediated Apoptosis by the Tumor Suppressor Par-4 -- Stem Cell Regulation by Death Ligands and Their Use in Cell Therapy -- Atypical Immune Functions of CD95/CD95L -- TLR3 is a Death Receptor Target in Cancer Therapy -- Fas/CD95, Lipid Rafts and Cancer -- Role of Sphingolipids in Death Receptor Signalling -- Post-Translational Modifications and Death Receptor Signalling -- System Modeling of Receptor-Induced Apoptosis.
520 $a This volume provides the current understanding of death receptor's/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy. But an increasing body of evidence suggests that some of these receptors may also contribute to tumorigenesis, or that new players such as TLR3 may be targeted for cancer therapy due to their ability to behave like death receptors.
650 0 $a Cancer $x Treatment. $3 661325
650 0 $a Apoptosis. $3 581343
650 0 $a Cell receptors. $3 668471
650 0 $a Tumor necrosis factor $x Receptors. $3 1198593
650 1 4 $a Biomedicine. $3 593880
650 2 4 $a Cancer Research. $3 668358
700 1 $a Micheau, Olivier. $3 1198592
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a Resistance to targeted anti-cancer therapeutics ; $v v.4. $3 1063064
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-56805-8
950 $a Biomedical and Life Sciences (Springer-11642)